An Open-Label, Randomized, Crossover Study to Assess the Pharmacokinetic and Pharmacodynamic Profiles of Once Daily and Twice Daily Dose Regimens of Recombinant Human Parathyroid Hormone (rhPTH[1-84]) Administered Subcutaneously to Subjects With Hypoparathyroidism

Trial Profile

An Open-Label, Randomized, Crossover Study to Assess the Pharmacokinetic and Pharmacodynamic Profiles of Once Daily and Twice Daily Dose Regimens of Recombinant Human Parathyroid Hormone (rhPTH[1-84]) Administered Subcutaneously to Subjects With Hypoparathyroidism

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Sep 2017

At a glance

  • Drugs Parathyroid hormone (Primary) ; Calcium
  • Indications Hypoparathyroidism
  • Focus Pharmacodynamics; Pharmacokinetics
  • Acronyms PARALLAX
  • Sponsors Shire
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 29 Sep 2016 Status changed from not yet recruiting to recruiting.
    • 23 Aug 2016 Planned primary completion date changed from 1 Nov 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top